Tasquinimod is an oral S100A9 inhibitor being evaluated in multiple myeloma.
SparkCures ID | 382 |
---|---|
Developed By | Active Biotech AB |
Generic Name | Tasquinimod |
Additional Names | ABR-215050, CID 54682876 |
Treatment Classifications |
|
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.